Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries

Source: MDLinx, April 2021

Because of the adoption of immune checkpoint inhibitor and targeted therapies since 2011, the therapeutic landscape of melanoma has changed dramatically, researchers sought to quantify the impacts of these changes on short-term treatment costs by comparing the first-year cancer-attributable costs in the novel (2011-2015) and historical (2004-2010) treatment eras.

READ THE ORIGINAL FULL ARTICLE
Menu